Join to View Full Profile
12902 Usf Magnolia DrTampa, FL 33612
Phone+1 813-745-2916
Dr. Wach is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Michael Wach is a surgical oncologist based in Tampa, FL, with subspecialties in peritoneal surface malignancies. He graduated magna cum laude in 2015 from the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo, where he also completed his surgical residency. Dr. Wach has expertise in treating colorectal and appendix cancers. His research contributions include several publications in prominent journals such as Annals of Surgical Oncology and Cancer Discovery, focusing on various facets of surgical oncology and related outcomes.
Education & Training
University at BuffaloResidency, Surgery, 2015- Jacobs School of Medicine and Biomedical Sciences at the University at BuffaloClass of 2015
Certifications & Licensure
FL State Medical License 2024 - 2028
VA State Medical License 2016 - 2026
PA State Medical License 2022 - 2024
American Board of Surgery Surgery- American Board of Surgery Complex General Surgical Oncology
Publications & Presentations
PubMed
- A Retrospective Examination of Neoadjuvant Chemotherapy for Metachronous Colorectal Peritoneal Metastases Prior to CRS/HIPEC.Michael M Wach, Hannah Bank, Kathrine Kelly, Thien Le, Joshua Derby
Annals of Surgical Oncology. 2026-07-01 - ASO Visual Abstract: A Retrospective Examination of Neoadjuvant Chemotherapy for Metachronous Colorectal Peritoneal Metastases Prior to CRS/HIPEC.Michael M Wach, Hannah Bank, Kathrine Kelly, Thien Le, Joshua Derby
Annals of Surgical Oncology. 2026-07-01 - ASO Author Reflections: Neoadjuvant Chemotherapy Prior to CRS/HIPEC for Metachronous Colorectal Peritoneal Metastases: No Survival Gain and Increased Perioperative Risk.Hannah Bank, Michael M Wach, Melanie Ongchin
Annals of Surgical Oncology. 2026-07-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
